2025 United States Adult Vaccine Market Revenue Opportunities Report
Description
The 2025 United States Adult Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adult Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the adult vaccine market in the United States are Pfizer Inc., GlaxoSmithKline (GSK), Merck & Co., Inc., and Sanofi S.A. Pfizer leads with its innovations in mRNA and protein subunit vaccines, having played a major role with its COVID-19 vaccine and maintaining strong positions in pneumococcal and meningococcal vaccines. GSK excels in herpes zoster (Shingrix), influenza, and hepatitis vaccines, using advanced adjuvants and recombinant technologies focused on adult immunization. Merck is known for HPV (Gardasil), pneumococcal, hepatitis, and MMR vaccines, emphasizing real-world effectiveness data and global health partnerships. Sanofi specializes in influenza, meningococcal, and combination vaccines and invests in innovative platforms like mRNA and recombinant proteins to address diverse adult needs in the US and globally.
These companies maintain vast manufacturing networks and strategic alliances that support vaccine distribution and development within the US market. They supply vaccines widely used in adult immunization programs, including influenza and pneumococcal vaccines, with a focus on innovation and regulatory approvals. Pfizer and Moderna notably led rapid COVID-19 vaccine deployment using mRNA technology in the US. Sanofi and GSK also continue to supply millions of adult doses annually for flu and other diseases, playing key roles in the US's public health vaccination efforts. Their extensive portfolios and market presence make them dominant players shaping the adult vaccine sector in the United States.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adult Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the adult vaccine market in the United States are Pfizer Inc., GlaxoSmithKline (GSK), Merck & Co., Inc., and Sanofi S.A. Pfizer leads with its innovations in mRNA and protein subunit vaccines, having played a major role with its COVID-19 vaccine and maintaining strong positions in pneumococcal and meningococcal vaccines. GSK excels in herpes zoster (Shingrix), influenza, and hepatitis vaccines, using advanced adjuvants and recombinant technologies focused on adult immunization. Merck is known for HPV (Gardasil), pneumococcal, hepatitis, and MMR vaccines, emphasizing real-world effectiveness data and global health partnerships. Sanofi specializes in influenza, meningococcal, and combination vaccines and invests in innovative platforms like mRNA and recombinant proteins to address diverse adult needs in the US and globally.
These companies maintain vast manufacturing networks and strategic alliances that support vaccine distribution and development within the US market. They supply vaccines widely used in adult immunization programs, including influenza and pneumococcal vaccines, with a focus on innovation and regulatory approvals. Pfizer and Moderna notably led rapid COVID-19 vaccine deployment using mRNA technology in the US. Sanofi and GSK also continue to supply millions of adult doses annually for flu and other diseases, playing key roles in the US's public health vaccination efforts. Their extensive portfolios and market presence make them dominant players shaping the adult vaccine sector in the United States.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
